Health-related quality of life among breast cancer patients in India

Purpose This study evaluated the health-related quality of life (HRQoL) among breast cancer patients during various phases of treatment and with different treatment modalities, which helps in monitoring treatment outcomes, assessing the well-being of patients, and conducting health technology assess...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2022-12, Vol.30 (12), p.9983-9990
Main Authors: Gupta, Nidhi, Pandey, Awadhesh Kumar, Dimri, Kislay, Jyani, Gaurav, Goyal, Aarti, Prinja, Shankar
Format: Article
Language:English
Subjects:
Breast cancer
Cancer
Cancer patients
Cancer therapies
Care and treatment
Chemotherapy
Epidemiology
Health aspects
Medical research
Medicine
Medicine & Public Health
Medicine, Experimental
Nursing
Nursing Research
Oncology
Pain Medicine
Patient compliance
Quality of life
Rehabilitation
Rehabilitation Medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose This study evaluated the health-related quality of life (HRQoL) among breast cancer patients during various phases of treatment and with different treatment modalities, which helps in monitoring treatment outcomes, assessing the well-being of patients, and conducting health technology assessments. Methods A total of 534 interviews were conducted among the patients of breast cancer recruited at different stages of disease and with different treatment modalities. HRQoL was determined using EuroQoL five dimensions questionnaire with five levels (EQ-5D-5L), EuroQoL Visual Analogue Scale (EQ VAS), and the EORTC QLQ-BR23 instrument. The utility values were determined based on the Indian EQ-5D-5L value set. The socio-demographic and clinico-therapeutic determinants of HRQoL were evaluated using multiple linear regression. Results The mean utility value of breast cancer patients was 0.602 (SD = 0.311) and mean EQ VAS score was 75 (SD = 12.3). The mean utility value at diagnosis was 0.628, whereas utility value was 0.55, 0.595, and 0.64 for post-surgery, post-chemotherapy, and post-radiotherapy treatment groups, respectively. The most frequently reported problem was pain/discomfort (in 84.3% patients), followed by anxiety/depression (83.5%). On EORTC QLQ-BR23, the maximum symptom scale scores for systemic therapy side effects were reported in the post chemotherapy group. The body image score and future perspective score were better in patients undergoing breast conservative surgery (BCS) compared to patients undergoing modified radical mastectomy. Age, education, and employment status of the patient, type of treatment modality, and use of taxanes are the determinants of HRQoL in breast cancer patients. Conclusion Clinical interventions should focus upon management of pain and anxiety. BCS should be offered to all eligible patients as it is associated with better HRQoL. Addressing the factors that independently affect the HRQoL will help in improving the treatment compliance and outcomes.
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-022-07395-7